Outlook Therapeutics (OTLK) Shares Outstanding (Weighted Average) (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Shares Outstanding (Weighted Average) data on file, last reported at $70.9 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $70.9 million, up 129.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $70.9 million (up 129.65% YoY), and the FY2025 annual result was $34.8 million, up 87.59% from the prior year.
• Shares Outstanding (Weighted Average) improved to $70.9 million in Q1 2026 per OTLK's latest filing, from $60.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $227.4 million in Q4 2022 and troughed at $12.1 million in Q1 2023.
• A 5-year average of $71.8 million and a median of $30.9 million in 2025 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) plunged 94.4% in 2023, then soared 148.43% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $227.4 million in 2022, then slumped by 94.28% to $13.0 million in 2023, then soared by 86.23% to $24.2 million in 2024, then soared by 148.43% to $60.2 million in 2025, then climbed by 17.77% to $70.9 million in 2026.
• Business Quant data shows OTLK's Shares Outstanding (Weighted Average) at $70.9 million in Q1 2026, $60.2 million in Q4 2025, and $34.8 million in Q3 2025.